{"id":82,"date":"2015-03-03T17:17:33","date_gmt":"2015-03-03T17:17:33","guid":{"rendered":"http:\/\/caltagmedsystems.co.uk\/information\/?p=82"},"modified":"2025-05-29T16:48:11","modified_gmt":"2025-05-29T16:48:11","slug":"caesin-kinase-2-assay-inhibitor-screening-kit","status":"publish","type":"post","link":"https:\/\/www.caltagmedsystems.co.uk\/information\/caesin-kinase-2-assay-inhibitor-screening-kit\/","title":{"rendered":"Caesin Kinase-2 Assay \/ Inhibitor Screening Kit"},"content":{"rendered":"\n<p>The CycLex\u00ae CK2 Assay \/ Inhibitor Screening Kit is designed to measure the activity of purified Casein Kinase-2 (CK2) for the rapid and sensitive evaluation of CK2 inhibitors or activators. The phospho-specific monoclonal antibody used in this CK2 assay kit specifically recognises the phospho-serine46 residue in p53, which is phosphorylated by CK2 in vitro.<\/p>\n\n\n\n<p>Protein kinase CK2 is a ubiquitous and pleiotropic serine\/threonine protein kinase that interacts with many different signalling pathways, especially those involved in specific phases of the cell cycle. The holoenzyme is composed of two catalytic (\u03b1 and\/or \u03b1&#8217;) and two regulatory (\u03b2) subunits. Both the free \u03b1\/\u03b1&#8217; catalytic subunits and the holoenzyme are constitutively active, a feature that is suspected to underlie CK2\u2019s oncogenic potential. The enzyme is highly expressed in most cancers, and research suggests that CK2 dysregulation in tumours may influence their apoptotic activity. Thus, CK2 is an attractive target for anti-neoplastic and anti-tumour drugs.<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter\"><a href=\"http:\/\/www.caltagmedsystems.co.uk\/pricing_ordering\/product_detail.php?CI_ID=169029\"><img loading=\"lazy\" decoding=\"async\" width=\"250\" height=\"230\" src=\"http:\/\/caltagmedsystems.co.uk\/information\/wp-content\/uploads\/CK2-Assay-kit.png\" alt=\"CK2-Assay-kit\" class=\"wp-image-83\"\/><\/a><figcaption class=\"wp-element-caption\">Fig. 1 Dose dependency of the recombinant CK2 enzyme reaction, measured using the CycLex\u00ae CK2 assay kit with positive controls CK2 \u03b1\/\u03b2 and CK2 \u03b1\u2019\/\u03b2.<\/figcaption><\/figure>\n\n\n\n<h3 class=\"wp-block-heading clear\"><span style=\"color: #21318f;\">Product Information<\/span><\/h3>\n\n\n\n<p><a href=\"https:\/\/www.caltagmedsystems.co.uk\/pricing_ordering\/product_detail.php?CI_ID=1616892&amp;group_1=All&amp;group_2=All&amp;supplier=10&amp;clonality=All&amp;host=All&amp;species=All&amp;applications=All&amp;regulatory_status=All&amp;searchwords=cyclex\">CycLex\u00ae Casein kinase-2 (CK2) Assay \/ Inhibitor Screening Kit (96 wells)<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span style=\"color: #21318f;\">Related Products<\/span><\/h3>\n\n\n\n<p><a href=\"https:\/\/www.caltagmedsystems.co.uk\/pricing_ordering\/product_detail.php?CI_ID=1616970&amp;group_1=All&amp;group_2=All&amp;supplier=10&amp;clonality=All&amp;host=All&amp;species=All&amp;applications=All&amp;regulatory_status=All&amp;searchwords=ck2\">CK2 (\u03b1\/\u03b2) Positive Control<\/a><\/p>\n\n\n\n<p>To view MBL&#8217;s catalogue of Kinase Assay Kits, please click<a title=\"Kinase Assay Kits Brochure\" href=\"http:\/\/www.caltagmedsystems.co.uk\/docs\/MBLI_Kinase_Brochure_0.pdf\"> here.<\/a><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span style=\"color: #21318f;\">References<\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a title=\"CK2 Assay kit ref 1 caesin kinase 2 assay kit\" href=\"http:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/bi00488a034\">Lozeman et al (1990) Isolation and characterization of human cDNA clones encoding the alpha and the alpha&#8217; subunits of casein kinase II. <em>Biochemistry<\/em> <strong>29<\/strong> (36):8436-47<\/a><\/li>\n\n\n\n<li><a title=\"CK2 Assay Kit ref 2\" href=\"http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1432-1033.1990.tb15484.x\/abstract;jsessionid=7A943A4CD5B2A3DD16090BC85891B284.f04t03\">M\u00fcnstermann et al (1990) Casein kinase II is elevated in solid human tumours and rapidly proliferating non-neoplastic tissue. <em>European Journal of Biochemistry<\/em> <strong>189<\/strong> (2): 251-257<\/a><\/li>\n\n\n\n<li><a title=\"CK2 Assay kit ref 3\" href=\"http:\/\/www.jbc.org\/content\/269\/9\/6986.full.pdf+html\">Pepperkok et al (1994). Casein Kinase I1 Is Required for Transition of GdG1, Early GI, and G1\/S Phases of the Cell Cycle. <em>Journal Of Biological Chemistry<\/em> <strong>269<\/strong> (9): 6986-6991<\/a><\/li>\n\n\n\n<li><a title=\"CK2 Assay kit ref 3 caesin kinase assay \" href=\"http:\/\/www.nature.com\/onc\/journal\/v21\/n34\/pdf\/1205640a.pdf\">Channavajhala P, Seldin D (2002). Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. <em>Oncogene<\/em> <strong>21<\/strong>: 5280 \u2013 5288<\/a><\/li>\n\n\n\n<li><a title=\"CK2 Assay kit ref 5 Caesin Kinase assay kit\" href=\"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1097276501003355\">Desagher et al (2001). Phosphorylation of Bid by Casein Kinases I and II Regulates Its Cleavage by Caspase 8. <em>Molecular Cell<\/em> <strong>8<\/strong> (3): 602-611<\/a><\/li>\n\n\n\n<li><a title=\"CK2 Assay kit ref 6 caesin kinase 2 assay kit\" href=\"http:\/\/link.springer.com\/article\/10.1023\/A%3A1013112908734\">Wang et al (2001). Response of cancer cells to molecular interruption of the CK2 signal <em>Molecular and Cellular Biochemistry<\/em> <strong>227<\/strong> (1-2): 167-174<\/a><\/li>\n\n\n\n<li><a title=\"CK2 Assay kit ref 7 caesin kinase assay kit\" href=\"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1097276502006007\">Li et al (2002) Phosphorylation by Protein Kinase CK2: A Signaling Switch for the Caspase-Inhibiting Protein ARC. <em>Molecular Cell<\/em> <strong>10<\/strong> (2): 247-258<\/a><\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-alpha-channel-opacity has-background\" style=\"background-color:#21318f;color:#21318f\"\/>\n\n\n\n<p><a class=\"notion-link-token notion-focusable-token notion-enable-hover\" tabindex=\"0\" data-token-index=\"0\" href=\"https:\/\/www.caltagmedsystems.co.uk\/\" rel=\"noopener noreferrer\"><span class=\"link-annotation-unknown-block-id--1999865189\">Caltag Medsystems <\/span><\/a>is the distributor of <a href=\"https:\/\/www.caltagmedsystems.co.uk\/mbl\/\"><span class=\"link-annotation-unknown-block-id--1796071570\">MBL&#8217;s<\/span> <\/a>products in the UK and Ireland. If you have any questions about these products, please <a class=\"notion-link-token notion-focusable-token notion-enable-hover\" tabindex=\"0\" data-token-index=\"5\" href=\"https:\/\/www.caltagmedsystems.co.uk\/contact.php\" rel=\"noopener noreferrer\"><span class=\"link-annotation-unknown-block-id--1821305553\">contact<\/span><\/a> <a class=\"notion-link-token notion-focusable-token notion-enable-hover\" tabindex=\"0\" data-token-index=\"7\" href=\"https:\/\/www.caltagmedsystems.co.uk\/contact.php\" rel=\"noopener noreferrer\"><span class=\"link-annotation-unknown-block-id--1821305553\">us<\/span><\/a>.<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The CycLex\u00ae CK2 Assay \/ Inhibitor Screening Kit measures the activity of purified CK2 for rapid &#038; sensitive evaluation of CK2 inhibitors or activators.<\/p>\n","protected":false},"author":13,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,11],"tags":[918,1042,272,917],"class_list":["post-82","post","type-post","status-publish","format-standard","hentry","category-cell-signalling","category-serinethreonine-kinase","tag-caesin-kinase-2","tag-cyclex","tag-mbl","tag-screening-kit"],"_links":{"self":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/82","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/comments?post=82"}],"version-history":[{"count":19,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/82\/revisions"}],"predecessor-version":[{"id":12293,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/posts\/82\/revisions\/12293"}],"wp:attachment":[{"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/media?parent=82"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/categories?post=82"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-json\/wp\/v2\/tags?post=82"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}